| 摘要 |
Disclosed is a method of crystallizing (1R,5S,6S)-2- ¢(6,7-dihydro-5H-pyrazolo¢1,2-a!¢1,2,4!triazolium-6-yl)!thio-6- ¢(R)-1-hydroxyethyl!-1-methyl-carbapenem-3-carboxylate (hereinafter simply referred to as L-627), by maintaining an aqueous solution of L-627 at a temperature in the range from the eutectic temperature of the solution to a temperature lower than 0.degree.C. The method provides such advantages that loss of L-627 accompanied by crystallization is reduced, the number of steps in the preparation of vial formulations is small and maintenance of these steps under sterile and dust-free conditions can be performed easily, dispensing of the drug can be conducted with quantitative accuracy, and the crystals promptly dissolve in a solvent at the time of use.
|
